Core Viewpoint - Firefly Neuroscience has made a significant acquisition of Evoke Neuroscience, aiming to enhance its brain health assessment capabilities through advanced technology and a proprietary database [1][2]. Acquisition Details - The acquisition involves a payment of $6 million, split equally between cash and Firefly's common stock, with a share price set at $3.50. Evoke's investors may receive a $500,000 performance bonus if Evoke achieves at least $3 million in annual revenue within three years [2]. - Post-acquisition, Firefly will gain access to over 180,000 standardized EEG/ERP assessment records, 27 authorized patents, and more than 60 commercial users [2]. Stock Performance - Following the announcement of joining NVIDIA's Connect program in February 2025, Firefly's stock surged over 170% on February 11, with a total increase of nearly 400% over three days [3]. Core Technology - Firefly's primary technology, the Brain Network Analysis (BNA™) system, utilizes advanced AI and a proprietary EEG database to provide comprehensive assessments of brain health, significantly impacting the diagnosis and monitoring of conditions like depression and dementia [5][6]. Database Development - The company has established a patented standardized high-definition longitudinal EEG database comprising over 17,000 patients across 12 diseases, including normal clinical patients [6]. Technology Application - BNA™ is integrated with FDA-approved EEG systems, offering clinicians detailed insights into brain function, enhancing their ability to diagnose mental and cognitive disorders accurately [8]. Commercialization Strategy - Firefly is commercializing BNA™, targeting pharmaceutical companies involved in drug research and clinical trials, as well as healthcare professionals [10]. Strategic Partnerships - In 2024, Firefly formed a strategic partnership with the Dallas Neurology Consultants (NCD) to incorporate BNA™ into patient workflows and conduct clinical research aimed at identifying biomarkers for predicting dementia [11]. - Firefly also announced a partnership with Zeto in September 2024 to integrate its BNA™ technology with Zeto's EEG platform, which is now used in over 200 hospitals and neurology departments in the U.S. [13][15]. Recent Developments - On October 15, 2024, Firefly's BNA™ biomarker discovery AI platform was approved to support Arrivo Bioventures in its exploratory study of a novel SIRT6 activator in healthy volunteers and patients with major depressive disorder [17]. - On October 16, 2024, Firefly announced a collaboration with Bright Minds Biosciences to analyze data from its first human Phase I study of a leading compound [17]. About Evoke Neuroscience - Founded in 2009, Evoke Neuroscience focuses on brain health assessment and cognitive function diagnostics, utilizing innovative EEG technology to track brain health over time [20]. - Evoke has developed EEG-based neuromodulation and neurofeedback systems that create personalized treatment plans based on patients' EEG data [22].